Daiichi Sankyo Company, Limited is pleased to announce that it recently entered into an outsourcing agreement with AstraZeneca K.K. (hereinafter, AstraZeneca) to manufacture the AstraZeneca-developed COVID-19 vaccine, AZD1222, in Japan.
In order to play a part in the COVID-19 vaccine manufacturing and supply scheme agreed upon between AstraZeneca and the government of Japan, Daiichi Sankyo will use undiluted solutions provided by AstraZeneca to manufacture COVID-19 vaccines in the country, including vial filling and packaging, in accordance with the outsourcing agreement.
The manufacture of the COVID-19 vaccine, AZD1222, will be undertaken by Daiichi Sankyo Biotech Company, Limited, a subsidiary of Daiichi Sankyo, at a facility dedicated to the Ministry of Health, Labour and Welfare’s “project to establish a system for developing and producing novel influenza virus vaccines.”
As it strives to help restore safety and security in society through the early eradication of COVID-19, Daiichi Sankyo, in addition to ensuring the stable supply of the AstraZeneca COVID-19 vaccine in Japan, will continue to work to advance ongoing research and development of a Nafamostat inhalation formulation (DS-2319) as well as an mRNA vaccine (DS-5670)
